Trends in Net Survival from Vulvar Squamous Cell Carcinoma in Italy (1990-2015).
survival
trend
vulvar neoplasms
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
10 Mar 2023
10 Mar 2023
Historique:
received:
17
01
2023
revised:
27
02
2023
accepted:
06
03
2023
medline:
30
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
(1) Objective: In many Western countries, survival from vulvar squamous cell carcinoma (VSCC) has been stagnating for decades or has increased insufficiently from a clinical perspective. In Italy, previous studies on cancer survival have not taken vulvar cancer into consideration or have pooled patients with vulvar and vaginal cancer. To bridge this knowledge gap, we report the trend in survival from vulvar cancer between 1990 and 2015. (2) Methods: Thirty-eight local cancer registries covering 49% of the national female population contributed the records of 6274 patients. Study endpoints included 1- and 2-year net survival (NS) calculated using the Pohar-Perme estimator and 5-year NS conditional on having survived two years (5|2-year CNS). The significance of survival trends was assessed with the Wald test on the coefficient of the period of diagnosis, entered as a continuous regressor in a Poisson regression model. (3) Results: The median patient age was stable at 76 years. One-year NS decreased from 83.9% in 1990-2001 to 81.9% in 2009-2015 and 2-year NS from 72.2% to 70.5%. Five|2-year CNS increased from 85.7% to 86.7%. These trends were not significant. In the age stratum 70-79 years, a weakly significant decrease in 2-year NS from 71.4% to 65.7% occurred. Multivariate analysis adjusting for age group at diagnosis and geographic area showed an excess risk of death at 5|2-years, of borderline significance, in 2003-2015 versus 1990-2002. (4) Conclusions: One- and 2-year NS and 5|2-year CNS showed no improvements. Current strategies for VSCC control need to be revised both in Italy and at the global level.
Identifiants
pubmed: 36983173
pii: jcm12062172
doi: 10.3390/jcm12062172
pmc: PMC10054662
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Italian Ministry of Health
ID : Wfn101L1
Références
J Low Genit Tract Dis. 2018 Jul;22(3):264-265
pubmed: 29933292
Cancers (Basel). 2022 Jan 13;14(2):
pubmed: 35053552
Int J Gynecol Cancer. 2022 Mar;32(3):332-337
pubmed: 35256420
Int J Cancer. 2018 Mar 15;142(6):1158-1165
pubmed: 29090456
Expert Opin Orphan Drugs. 2016;4(1):93-103
pubmed: 32765971
J Cancer Res Clin Oncol. 2016 Jun;142(6):1331-41
pubmed: 26973058
Clin Epidemiol. 2019 Jan 03;11:53-65
pubmed: 30655705
J Reprod Med. 2000 Aug;45(8):613-5
pubmed: 10986677
Int J Gynecol Cancer. 2009 May;19(4):741-4
pubmed: 19509581
Int J Gynecol Cancer. 2022 Jul 4;32(7):830-845
pubmed: 35728950
Epidemiol Prev. 2017 Mar-Apr;41(2 Suppl 1):1-244
pubmed: 28629213
Ann Oncol. 2020 Feb;31(2):213-227
pubmed: 31959338
BJOG. 2014 May;121(6):728-38; discussion 739
pubmed: 24148762
Cancer Epidemiol Biomarkers Prev. 2016 Aug;25(8):1224-30
pubmed: 27257093
Int J Gynecol Cancer. 2012 Jun;22(5):854-9
pubmed: 22426405
Acta Oncol. 2018 Mar;57(3):324-330
pubmed: 28799431
Obstet Gynecol. 2006 Dec;108(6):1361-8
pubmed: 17138767
JNCI Cancer Spectr. 2020 Sep 14;4(6):pkaa078
pubmed: 33409455
Int J Cancer. 2021 Feb 15;148(4):835-844
pubmed: 33405292
J Eur Acad Dermatol Venereol. 2022 Jul;36(7):952-972
pubmed: 35411963
Sci Rep. 2021 Mar 11;11(1):5661
pubmed: 33707570
Gynecol Oncol. 2014 Aug;134(2):314-8
pubmed: 24875124
Eur J Cancer. 2013 Dec;49(18):3872-80
pubmed: 24011936
BMC Cancer. 2018 Aug 30;18(1):858
pubmed: 30165835
Cancers (Basel). 2021 Mar 19;13(6):
pubmed: 33808776
Menopause. 2020 Oct 26;28(2):119-125
pubmed: 33109996
Melanoma Res. 2010 Oct;20(5):422-6
pubmed: 20679908
Br J Cancer. 2009 Dec 3;101 Suppl 2:S102-9
pubmed: 19956153
Gynecol Oncol. 2017 Jun;145(3):543-548
pubmed: 28356187
Chin Clin Oncol. 2021 Apr;10(2):19
pubmed: 33353362
J Dtsch Dermatol Ges. 2019 Oct;17(10):1069-1071
pubmed: 31631548
Lancet. 2014 Feb 8;383(9916):564-73
pubmed: 24351320
Stat Med. 2012 Apr 13;31(8):775-86
pubmed: 22281942
Gynecol Oncol. 2020 Jun;157(3):656-663
pubmed: 32273199
Eur J Cancer. 2004 Oct;40(15):2307-16
pubmed: 15454257
Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1:7-18
pubmed: 34669204
Gynecol Oncol. 2020 Jun;157(3):664-670
pubmed: 32276790
Epidemiol Prev. 2016 Jan-Feb;40(1 Suppl 2):1-120
pubmed: 26951748
Biometrics. 2012 Mar;68(1):113-20
pubmed: 21689081
BMC Cancer. 2022 Apr 26;22(1):456
pubmed: 35473606
Gynecol Oncol. 2020 May;157(2):450-455
pubmed: 32037194
BMJ Open. 2018 Feb 23;8(2):e019005
pubmed: 29476028
Trials. 2018 May 10;19(1):291
pubmed: 29793540
Int J Clin Oncol. 2019 Sep;24(9):1137-1142
pubmed: 31025128
J Low Genit Tract Dis. 2021 Apr 1;25(2):166-171
pubmed: 33470738
CMAJ Open. 2014 Jul 22;2(3):E127-32
pubmed: 25114894
Int J Cancer. 2017 Dec 1;141(11):2174-2186
pubmed: 28730615
Int J Gynecol Pathol. 2006 Jan;25(1):22-9
pubmed: 16306780
Int J Gynecol Cancer. 2015 Jan;25(1):125-30
pubmed: 25398020
Cancer Prev Res (Phila). 2022 Nov 1;15(11):777-784
pubmed: 35969832
Int J Gynecol Cancer. 2015 Nov;25(9):1683-9
pubmed: 26495761
Curr Opin Obstet Gynecol. 2020 Feb;32(1):9-14
pubmed: 31876635
Int J Mol Sci. 2020 Dec 27;22(1):
pubmed: 33375467
Infect Agent Cancer. 2020 Apr 01;15:20
pubmed: 32266002
Lancet Oncol. 2013 Feb;14(2):109-10
pubmed: 23369681
Gynecol Oncol. 2011 Jul;122(1):45-9
pubmed: 21474166
J Obstet Gynaecol Res. 2022 Mar;48(3):533-540
pubmed: 34962334
J Gynecol Oncol. 2017 Jul;28(4):e27
pubmed: 28541626
Cancers (Basel). 2022 Mar 20;14(6):
pubmed: 35326732